Dual-payload antibody-drug conjugates (ADCs) represent a next-generation therapeutic strategy designed to overcome tumor heterogeneity and drug resistance by delivering two distinct payloads with synergistic potential. This study aimed to identify an optimal dual-payload combination to address the challenge of therapeutic resistance in colorectal cancer (CRC), focusing on inhibitors of DNA damage response (DDR) pathways.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
